Laurent Eckert1, Shaloo Gupta2, Caroline Amand3, Abhijit Gadkari4, Puneet Mahajan5, Joel M Gelfand6. 1. Sanofi, Chilly-Mazarin, France. Electronic address: Laurent.Eckert@sanofi.com. 2. Kantar Health, Princeton, New Jersey. 3. Sanofi, Chilly-Mazarin, France. 4. Regeneron Pharmaceuticals, Inc, Tarrytown, New York. 5. Sanofi, Bridgewater, New Jersey. 6. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Given its public health impact, there is need for broad and representative data on the humanistic burden of atopic dermatitis (AD). OBJECTIVE: To establish the humanistic burden of AD in US adults. METHODS: Data were from the 2013 US National Health and Wellness Survey; AD self-reports were propensity-matched with non-AD controls and with psoriasis controls. Bivariate analyses were conducted on burden outcomes between the AD and control groups. RESULTS: Demographics and baseline characteristics were comparable between matched groups. Subjects with AD (n = 349) versus non-AD controls (n = 698) had significantly higher rates of anxiety, depression, and sleep disorders (29.8%, 31.2%, and 33.2% vs 16.1%, 17.3%, and 19.2%, respectively [all P < .001]); a lower Short Form-36 v2 mental component summary score (44.5 vs 48.0, respectively [P < .001]); a lower physical component summary score (47.6 vs 49.5, respectively [P = .004]), and lower health utilities (0.67 vs 0.72, respectively [P < .001]) in addition to a higher work absenteeism rate (9.9% vs 3.6%, respectively [P < .001]) and activity impairment rate (33.6% vs 25.2%, respectively [P < .001]). Subjects with AD and psoriasis controls (n = 260 each) showed similar impairment in health-related quality of life and productivity. LIMITATIONS: Data were self-reported. CONCLUSION: AD is associated with a substantial humanistic burden that is similar in magnitude to that of psoriasis, which is also recognized for its debilitating symptoms, indicating the need for more effective treatments for AD.
BACKGROUND: Given its public health impact, there is need for broad and representative data on the humanistic burden of atopic dermatitis (AD). OBJECTIVE: To establish the humanistic burden of AD in US adults. METHODS: Data were from the 2013 US National Health and Wellness Survey; AD self-reports were propensity-matched with non-AD controls and with psoriasis controls. Bivariate analyses were conducted on burden outcomes between the AD and control groups. RESULTS: Demographics and baseline characteristics were comparable between matched groups. Subjects with AD (n = 349) versus non-AD controls (n = 698) had significantly higher rates of anxiety, depression, and sleep disorders (29.8%, 31.2%, and 33.2% vs 16.1%, 17.3%, and 19.2%, respectively [all P < .001]); a lower Short Form-36 v2 mental component summary score (44.5 vs 48.0, respectively [P < .001]); a lower physical component summary score (47.6 vs 49.5, respectively [P = .004]), and lower health utilities (0.67 vs 0.72, respectively [P < .001]) in addition to a higher work absenteeism rate (9.9% vs 3.6%, respectively [P < .001]) and activity impairment rate (33.6% vs 25.2%, respectively [P < .001]). Subjects with AD and psoriasis controls (n = 260 each) showed similar impairment in health-related quality of life and productivity. LIMITATIONS: Data were self-reported. CONCLUSION:AD is associated with a substantial humanistic burden that is similar in magnitude to that of psoriasis, which is also recognized for its debilitating symptoms, indicating the need for more effective treatments for AD.
Authors: Eric L Simpson; Emma Guttman-Yassky; David J Margolis; Steven R Feldman; Abrar Qureshi; Tissa Hata; Vera Mastey; Wenhui Wei; Laurent Eckert; Jingdong Chao; Renée J G Arnold; Tiffany Yu; Francis Vekeman; Mayte Suárez-Fariñas; Abhijit Gadkari Journal: JAMA Dermatol Date: 2018-08-01 Impact factor: 10.282
Authors: Jacob P Thyssen; Andreas W Brenneche; Maria E Madsen; Mikkel H Pedersen; Dennis J Trangbaek; Christian Vestergaard Journal: Acta Derm Venereol Date: 2021-09-03 Impact factor: 3.875
Authors: Lieneke F M Ariëns; Daphne S Bakker; Jorien van der Schaft; Floor M Garritsen; Judith L Thijs; Marjolein S de Bruin-Weller Journal: Ther Adv Chronic Dis Date: 2018-05-11 Impact factor: 5.091
Authors: Jonathan I Silverberg; Jacob P Thyssen; Eric L Simpson; Gil Yosipovitch; Sonja Ständer; Hernan Valdez; Ricardo Rojo; Pinaki Biswas; Daniela E Myers; Claire Feeney; Marco DiBonaventura Journal: Am J Clin Dermatol Date: 2021-05-05 Impact factor: 7.403
Authors: Steven R Feldman; Linda S Cox; Lindsay C Strowd; Robert A Gerber; Steven Faulkner; Debra Sierka; Timothy W Smith; Joseph C Cappelleri; Mark E Levenberg Journal: Am Health Drug Benefits Date: 2019-04